392 related articles for article (PubMed ID: 34230169)
1. Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
Shionoya Y; Hirohashi Y; Takahashi H; Hashimoto M; Nishiyama K; Takakuwa Y; Nakatsugawa M; Kubo T; Kanaseki T; Tsukahara T; Torigoe T
Anticancer Res; 2021 Jul; 41(7):3699-3706. PubMed ID: 34230169
[TBL] [Abstract][Full Text] [Related]
2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
3. Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
Zhang D; Zhang Y; Huang Y; Kong L; Yu J
Lung Cancer; 2020 Jan; 139():18-21. PubMed ID: 31704279
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
5. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
[TBL] [Abstract][Full Text] [Related]
6. Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues.
Fan TW; Higashi RM; Song H; Daneshmandi S; Mahan AL; Purdom MS; Bocklage TJ; Pittman TA; He D; Wang C; Lane AN
Elife; 2021 Aug; 10():. PubMed ID: 34406120
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
[TBL] [Abstract][Full Text] [Related]
8. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB
Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084
[TBL] [Abstract][Full Text] [Related]
10. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.
Chen R; Tao Y; Xu X; Shan L; Jiang H; Yin Q; Pei L; Cai F; Ma L; Yu Y
Discov Med; 2018 Oct; 26(143):155-166. PubMed ID: 30586539
[TBL] [Abstract][Full Text] [Related]
12. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Matsumoto H; Hirano K; Kominami R; Tomii K; Suzuki H; Hirashima T; Tanaka S; Uchida J; Morita M; Kanazu M; Mori M; Nagata K; Fukuda I; Tamiya M
BMC Cancer; 2021 Apr; 21(1):346. PubMed ID: 33794809
[TBL] [Abstract][Full Text] [Related]
13. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
14. Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer.
Singh N; Seetharamu N
BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32843385
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
19. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
20. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]